build with biology
Scalable Biotech Platform
NESBLY-Tech
At GENEON, we are developing NESBLY-tech, a high-performance DNA construction platform that makes building synthetic cells easy, scalable, precise, and affordable.
​
With NESBLY-tech, R&D teams in academia, biotech start-ups, and industry can unlock bold new possibilities in bioproduction. From a single platform, you can design and prototype complex DNA molecules of any size, from single genes to entire synthetic chromosomes, with speed, reliability and affordable costs.
Imagine what's possible
NESBLY-tech is the DNA platform that catalyzes these futures – giving innovators the tools to leapfrog into the green industrial revolution.
Precision fermentation
Brewing flavour switching animal-free dairy proteins in home fermenters, without a single cow in sight.
Bio-nanomachines
Programming microbial swarms to roam through soil, capturing rare metals for next-gen batteries.
Bioeconomy
Engineering mould-based biorefineries that turn waste streams into sustainable plastics and fabrics.
Roadmap
2024
Milestone 1
Proof-of-Concept
NESBLY enzymatic cocktail experimentally demonstrated - Completed
2025-2026
Milestone 2
MVP
Cloning kit & DNA construction automation platform -
Ongoing
2026
Milestone 3
Prototype
Prototype case study in environmental biotechnology
2027-2028
Pilot studies with industrial biotech & food-tech partners
Milestone 4
Pilot
2029-2030
Milestone 5
Scale-up
Scaled production of NESBLY-tech systems for international distribution
The Market
Synthetic Biology Market (2023): $16.3B | 25% CAGR
​
NESBLY-tech Serviceable Market (2030): $431M
​
Business Model: B2B & B2C; product lines with gross margins of 68–90%​